In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
In a retrospective national VA cohort of nearly 1 million Veterans, tobacco smoking duration criteria identified more screening-eligible patients and fewer missed lung cancer diagnoses than pack-year...
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
In an integrated phase 2 analysis of HPV-associated oropharyngeal cancer, FMISO PET-guided chemoradiotherapy de-escalation was associated with 97% 5-year overall survival in both the 30-Gy and 70-Gy...
A retrospective study presented at the American Society of Clinical Oncology 2025 annual meeting evaluated women with endometrial neuroendocrine tumors and found that adjuvant treatment with...
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
